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Abstract Continuous, noninvasive hemoglobin (SpHb)
monitoring provides clinicians with the trending of chan-
ges in hemoglobin, which has the potential to alter red
blood cell transfusion decision making. The objective of
this study was to evaluate the impact of SpHb monitoring
on blood transfusions in high blood loss surgery. In this
prospective cohort study, eligible patients scheduled for
neurosurgery were enrolled into either a Control Group or
an intervention group (SpHb Group). The Control Group
received intraoperative hemoglobin monitoring by inter-
mittent blood sampling when there was an estimated 15 %
blood loss. If the laboratory value indicated a hemoglobin
level of B10 g/dL, a red blood cell transfusion was started
and continued until the estimated blood loss was replaced
and a laboratory hemoglobin value was[l0 g/dL. In the
SpHb Group patients were monitored with a Radical-7
Pulse CO-Oximeter for continuous noninvasive hemoglo-
bin values. Transfusion was started when the SpHb value
fell to Bl0 g/dL and was continued until the SpHb was
Cl0 g/dL. Blood samples were taken pre and post trans-
fusion. Percent of patients transfused, average amount of
blood transfused in those who received transfusions and
the delay time from the hemoglobin reading of\10 g/dL
to the start of transfusion (transfusion delay) were com-
pared between groups. The trending ability of SpHb, and
the bias and precision of SpHb compared to the laboratory
hemoglobin were calculated. Compared to the Control
Group, the SpHb Group had fewer units of blood trans-
fused (1.0 vs 1.9 units for all patients; p B 0.001, and 2.3
vs 3.9 units in patients receiving transfusions; p B 0.0 l),
fewer patients receiving[3 units (32 vs 73 %; p B 0.01)
and a shorter time to transfusion after the need was
established (9.2 ± 1.7 vs 50.2 ± 7.9 min; p B 0.00 l).
The absolute accuracy of SpHb was 0.0 ± 0.8 g/dL and
trend accuracy yielded a coefficient of determination of
0.93. Adding SpHb monitoring to standard of care blood
management resulted in decreased blood utilization in
high blood loss neurosurgery, while facilitating earlier
transfusions.
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1 Introduction
Red blood cell (RBC) transfusions are initiated to maintain
oxygen transport and sustain life but transfusion practices
vary widely by hospital, procedure, and physician [1, 2].
Observational studies associate RBC transfusion with risk
in the form of postoperative infection [3], impaired pul-
monary function [4], and increased length of stay and
mortality [5, 6]. Meta-analyses of randomized controlled
trials indicate that restrictive transfusion practices are safe
and may provide benefit [7]. Additionally, RBC transfusion
is costly and a significant contributor to the expense of
surgical care [8].
These facts are balanced by the knowledge that anemia,
common amongst surgical patients, is also independently
associated with adverse outcomes [9]. Therefore, balancing
the need for RBC transfusion to mitigate anemia with the
risks associated with administration of blood products can
be a complicated aspect of care during and after surgery.
Laboratory hemoglobin (Hb) values are a primary indicator
for the need for blood transfusion [10], but are only
available intermittently and results can be delayed in the
period between blood draw and laboratory analysis. This
means that during surgery, initial and subsequent transfu-
sion decisions are often made without recent Hb results [1].
In addition to laboratory Hb values, point-of-care devices
such as the HemoCue (HemoCue, Angelhom, Sweden) can
be used in the operating room to detect Hb values; how-
ever, this point-of-care device is invasive, and requires
intermittent blood sample analysis. The HemoCue also
lacks the ability to provide real-time trends, hence limiting
its use in guiding blood management decisions [11]. Con-
tinuous monitoring of vital signs and estimated blood loss
help guide transfusion decisions in the absence of Hb;
however, these measures can be inaccurate and misleading
[12–14], leading to calls for real-time guidance of blood
loss [13].
Continuous and noninvasive hemoglobin (SpHb) moni-
toring is now possible with Pulse CO-Oximetry technology
and multi-wavelength sensors, which also provide tradi-
tional pulse oximetry measurements. SpHb monitoring
provides real-time trends in the values of hemoglobin,
indicating stable hemoglobin when it may be perceived to
be dropping and rising hemoglobin when it may be per-
ceived as not rising fast enough. SpHb monitoring has been
shown to help anesthesiologists reduce RBC transfusion
frequency and average units transfused per patient in a
randomized controlled trial in moderate to low blood loss
orthopedic surgery [15]. The objective of this study was to
evaluate SpHb monitoring impact on RBC transfusions in
high blood loss surgery. We hypothesized that the addi-
tional information provided by SpHb monitoring would
reduce red blood cell transfusion by preventing over
transfusion and decrease the time to start transfusions.
2 Materials and methods
2.1 Eligibility criteria
The protocol was approved by the Medical Research Ethics
Committee of Cairo University Faculty of Medicine. The
ethics committee waived the requirement for written
informed consent and considered the general surgical
informed consent to be sufficient for the study, given
Egyptian cultural considerations and the noninvasive nat-
ure of monitor and sensors. Patient charts were screened
the day prior to scheduled neurosurgery for inclusion and
exclusion criteria. A convenience sample of patients who
met the criteria was included in a prospective trial con-
ducted between February and August, 2012 in a tertiary
care, academic medical center. Adult patients between 15
and 60 years and scheduled to undergo neurosurgical
procedure were eligible for the study if they had an
American Society of Anesthesiologists (ASA) physical
status of I–II. Exclusion criteria included significant liver
disease defined as serum alanine aminotransferase and
serum aspartate aminotransferase[2.5 times normal, sig-
nificant renal disease defined as serum creatinine[1.5 mg/
dl or creatinine clearance\40 ml/min, pregnancy, signifi-
cant coagulopathy defined as international normalized ratio
[1.5, use of antiplatelets or anticoagulants, anemic
patients with Hb concentrations less than 10 g/dL, patients
scheduled for procedures with expected low blood loss
such as level 1 laminectomy, shunts, nerve decompression,
microdiscectomy, etc., and, any patient in whom simulta-
neous SpHb and Hb measurements could not be obtained.
2.2 Study design
In this prospective cohort study design, given the limita-
tions on the availability of the device and the number of
sensors that were available to use, only one patient
scheduled for neurosurgery the next day was randomly
selected using the sealed envelope method to be in the
SpHb Group. The remaining patients on that same day
were enrolled into a standard care group (Control Group).
Envelopes were prepared each day to match the number of
enrolled patients. Prior to surgery, patient demographic
information (gender, age, estimated weight, ASA status)
was recorded. All patients received standard-of-care peri-
operative monitoring and anesthesia per ASA guidelines by
the primary anesthesia care provider.
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2.3 Study procedures
Patients in the Control Group received intraoperative Hb
monitoring by intermittent blood sampling analyzed by the
central laboratory. An initial blood sample was taken prior
to surgery (baseline Hb) in all patients. Intra-operatively,
blood samples were taken when estimated blood loss
(EBL) was C15 % of total blood volume (Fig. 1). In the
SpHb Group, besides ASA monitoring and laboratory Hb,
patients were monitored with a Radical-7 Pulse CO-
Oximeter, v7748, connected to a R2-25 adult ReSposable
sensor (Revision E, Masimo, Irvine, CA) that displayed
continuous SpHb values. After induction of anesthesia, the
SpHb sensor was placed on the ring finger of the non-
dominant hand contralateral to the arterial line with the
emitter and detector of the sensor properly aligned per the
manufacturer’s directions for use. In both groups transfu-
sion was started when Hb was Bl0 g/dL, was continued
until the EBL was replaced to the next whole unit, and an
Hb value was confirmed to be[l0 g/dL. A blood sample
for laboratory analysis was taken prior to surgery (baseline
Hb), before each transfusion was started, and again when it
was discontinued. The Hb and SpHb values were recorded
on a case report form at baseline and before and after any
packed RBC transfusion.
Blood sampling technique was the same for both groups.
Arterial blood was drawn from a 20 gauge radial artery
cannula into 2 mL ethylenediaminetetraacetic acid collec-
tion tubes, thoroughly mixed then sent immediately to the
central lab for analysis by a single hematology analyzer
(GEN-S hematology analyzer, Beckman-Coulter Inc., Brea
CA). The hematology analyzer was calibrated daily
according to the manufactures directions for use and good
laboratory practice. All samples were processed and labo-
ratory values returned according to the standard practice of
the hospital. The variables recorded for each patient
included the time of each blood draw, the start time of each
transfusion, and the number of units of blood transfused
during the intraoperative period.
All anesthesiologists who participated in the study
treated patients in both groups. Blood loss for each patient
was estimated by the number of saturated sponges or sur-
gical gauze, the amount of suctioned blood in the waste
canister, and the amount of blood in the surgical field. Total
blood volume was estimated by multiplying the patient’s
weight by 75 mL/kg.
2.4 Data analysis
2.4.1 Sample size calculation
Historically, at our institution, it has been observed that
patients necessitating a blood transfusion would require an
average of 1.8 units of blood. Therefore, in order to detect a
33 % reduction in red blood cell units transfused with the
addition of SpHb monitoring (expected effect size equal to
0.6 units) with a standard deviation of 1.0 unit, and
assuming a a risk of 0.05 and a b risk of 0.20, 45 subjects
would be required for each group for a total of 90 patients.
Assuming 10 % of enrolled patients would not complete
the study we targeted enrollment of a minimum of 99
patients.
2.4.2 Effect on transfusion
The following transfusion variables were calculated and
compared between the SpHb Group and Control Group:Fig. 1 Flow diagram of Hb laboratory sample draws
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(a) average baseline Hb; (b) percent of patients transfused;
(c) average amount of blood transfused; (d) average change
in Hb from pre- to post-transfusion, and average amount
over or under hemoglobin target post-transfusion;
(e) average amount of blood transfused in those who
received transfusions; (f) number of patients that received 3
or more units of RBCs; (g) the average time between taking
the hemoglobin sample or SpHb measurement, and the start
of transfusion (transfusion delay); and, (h) the average total
blood loss.
2.4.3 SpHb absolute and trend accuracy
To assess absolute accuracy, or single point comparison,
paired SpHb and Hb measurements were compared pre-
and post-transfusion and bias and standard deviation were
calculated. A repeated measures Bland–Altman graph with
limits of agreement (1.96 9 standard deviation, adjusted
for the bias) was plotted to show agreement across the
range of values. To assess trending accuracy, a regression
plot of changes in Hb and corresponding changes in SpHb
was plotted and a coefficient of determination (R2) was
calculated.
For evaluation of differences between groups, two pro-
portion Z-tests, two sided t-tests or Mann–Whitney rank
sum tests for non-normally distributed data were per-




A total of 111 patients were enrolled with five patients
excluded due to protocol deviations: three in the Control
Group due to massive blood loss requiring transfusion to
start before the laboratory result was returned and two in
the SpHb Group due to the time delay between taking the
baseline Hb and the baseline SpHb.
The 106 patients who completed the study were 53 %
female and had an average age of 37.6 ± 14.1 (mean ± SD).
A total of 45 patients were included in the SpHb Group and
61 patients were included in the Control Group. A flow
diagram of the patient allocation is shown in Fig. 2. Patients
were scheduled for various neurosurgical procedures such as
frontal, temporal or occipital glioma excisions, meningioma
excisions and frontal, temporal and occipital mass excisions.
The proportion of surgery types was similar for both groups.
Patient demographics are shown in Table 1 with no signifi-
cant differences between groups except the SpHb group was
lower in weight.
3.2 Impact on transfusion
Transfusion variables are shown in Table 2. The SpHb
Group had mean baseline hemoglobin of approximately
1 g/dL lower than the Control Group. The percentage of
patients transfused in each group was not different, but
there were fewer RBC units transfused in the SpHb Group
versus the Control Group over all patients (1.0 vs 1.9 units;
p B 0.00 l) and in patients receiving transfusions (2.3 vs
3.9 units; p B 0.0 l). The SpHb Group also had a lower
percentage of transfused patients receiving[3 RBC units
(32 vs 73 %; p B 0.01). After RBC transfusion, the SpHb
had a lower Hb increase after RBC transfusion was initi-
ated (1.8 ± 0.9 vs 2.6 ± 1.2 g/dL; p B 0.05) and shorter
time to transfusion after transfusion need was established
(9.2 ± 1.7 vs 50.2 ± 7.9 min; p B 0.00 l).
3.3 Assessment of accuracy
For assessment of absolute accuracy, 83 SpHb and Hb
comparisons were made (45 baseline, 19 pre-transfusion,
and 19 post-transfusion). The bias and standard deviation
was 0.0 ± 0.8 g/dL over all comparisons, 0.1 ± 0.9 g/dL
for baseline Hb, -0.1 ± 0.8 g/dL for pre-transfusion Hb
and -0.1 ± 0.5 g/dL for post-transfusion Hb values. The
Bland–Altman plot for all values showed limits of agree-
ment of -1.6 to 1.5 g/dL (Fig. 3).
Trend accuracy analysis (change in consecutive SpHb
values compared to changes in time-matched consecutive
Hb values) showed a coefficient of determination (R2) of
0.96 (Fig. 4).
4 Discussion
Over 90 million times per year around the world, a phy-
sician makes the decision to transfuse blood [16]. Since
blood is an organ itself, this ‘‘liquid organ transplant’’ is
Fig. 2 Flow diagram of screened and included patients
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provided with good intentions and is billed as the ‘‘gift of
life’’. However, growing data indicate that blood may not
always be helpful to the patient and in fact, may expose the
patient to unwarranted risks, and hospitals and/or health
care systems to unnecessary costs.
Post-operatively, continuous hemoglobin trending could
provide added benefit by indicating hemorrhage that is
otherwise not apparent. This trending approach aligns well
with The Joint Commission’s call on hospitals to track
appropriateness of transfusions as a quality indicator [17].
Further, the American Medical Association and The Joint
Commission have targeted RBC transfusions as one of the
top five procedures in medicine for ‘‘overuse’’, defined as
using a treatment where the likelihood of benefit is negli-
gible and the patient is exposed to risk of harm [18].
In this study, our primary aim was to determine how a
new tool, SpHb monitoring, may impact transfusion deci-
sion making in high blood loss surgery when added to
standard practice. Our study showed that patients at risk for
high blood loss who received SpHb monitoring received
fewer RBC transfusions, on average. In this study, there
were no differences in percentage of patients transfused or
mean blood loss between the Control and SpHb Groups,
indicating that patients and procedures in both groups were
similar.
The baseline hemoglobin of the SpHb Group was
approximately 1 g/dL lower than the Control Group.
Multiple studies have shown that a lower baseline hemo-
globin significantly increases the likelihood of receiving a
RBC transfusion [19]. Therefore, the SpHb group should
have been more likely to receive a RBC transfusion in the
study. In our study, we observed no difference in the
overall transfusion rate (49 % in the Control Group, 42 %
in the SpHb Group) but we did observe a large difference
in the number of multi-unit transfusions, leading to a sig-
nificantly lower average units transfused in the SpHb
group. If both groups in our study had the same baseline
hemoglobin, it is possible that we might have also observed
Table 1 Patient characteristics
Demographics of 106
neurosurgery patients allocated
to Control Group (standard care
hemoglobin monitoring) or
SpHb Group (standard of care
plus SpHb monitoring) for
blood management
SD standard deviation
Control group SpHb group p value
No. of patients 61 45 –
Gender (M/F) (%) 49/51 44/55 –
Age range (y) 13–60 12–60 0.66
Weight, range (kg) 44–76 42–74 0.03
ASA Status I/II (%) 78/21 64/35 0.11
Procedures n (%) 61 45
Glioma excision 12 (20) 11 (24)
Meningioma excision 11 (18) 10 (22)
Frontal/temporal/occipital mass excision 4 (7) 4 (9)
Other (e.g. frontal lobectomy, depressed compound skull fracture,
cerebral vascular anastomosis, pituitary adenoma)
34 (56) 20 (44)
Table 2 Transfusion variables
Control group (n = 61) SpHb group (n = 45) p value
Baseline Hb (mean ± SD, g/dL) 12.4 ± 1.6 11.5 ± 1.0 0.02
Total blood loss (mean ± SD, mL) 1,807 ± 794 1,732 ± 804 0.30
Percent blood loss (total blood loss/estimated total blood volume) (%) 21.7 ± 16.4 27.7 ± 25.8 0.18
Pre-transfusion Hb (mean ± SD, g/dL) 8.3 ± 1.2 8.6 ± 1.3 0.23
Post-transfusion Hb (mean ± SD, g/dL) 10.8 ± 0.5 10.3 ± 0.5 \0.01
Change in Hb, pre-transfusion to post-transfusion (mean ± SD, mL) 2.6 ± 1.2 1.8 ± 0.9 \0.05
Patients transfused, n (%) 30 (49) 19 (42) 0.61
RBC units transfused per patient over all patients (mean ± SD) 1.9 ± 2.3 1.0 ± 1.5 0.01
RBC units transfused per transfused patient (mean ± SD, units) 3.9 ± 1.7 2.3 ± 1.5 \0.01
Transfused patients receiving[3 RBC units (%) 73 32 \0.01
Transfusion delay from determination of need (min) 50.2 ± 7.9 9.2 ± 1.7 \0.001
Transfusion variables for neurosurgery patients in Control Group (standard care hemoglobin monitoring and SpHb Group (SpHb monitoring) for
blood management
SD standard deviation
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a difference in the overall transfusion rate, as was previ-
ously shown in a randomized trial of SpHb monitoring in
lower blood loss orthopedic surgery, in which the RBC
transfusion rate was 4.5 % in the Control Group and 0.6 %
in the SpHb Group [15].
In contrast, the lower average RBC units transfused in
our study were primarily due to the differences in multi-
unit transfusions, as 32 % of the patients in the SpHb
Group received three or more RBC units versus 73 % in
the Control Group. This may have occurred due to the
ability of the anesthesiologist to gauge in real-time that the
transfusion had achieved the desired, increased effect on
hemoglobin levels, therefore preventing the decision to
have additional RBC units transfused. Further, the real time
assessment also affected the initial decision to transfuse,
resulting in a quicker decision to initiate a transfusion when
needed due to a lack of delay in laboratory Hb values. It is
unlikely that the full benefit of continuous monitoring
could be achieved by a more diligent assessment of Hb
levels using standard procedures. When using laboratory
values, the inherent lag time from the request of a test to
obtaining the result would be too great, and using an
invasive point-of-care device would still require clinician
initiative to request a test, therefore, unexpected changes,
or unexpected stabilization of hemoglobin, would not be
detected.
It is important to note that although the post-transfusion
Hb was different between groups with the Control Group
being higher, the mean post-transfusion hemoglobin of the
SpHb Group was not in the anemic range of \10 g/dL.
Anemia is a risk factor for surgical patients, but may be of
a special concern to neurosurgical patients. Subarachnoid
Haemorrhage [20], traumatic brain injury [21], and other
neurosurgical patients [22] have worse outcomes if they are
anemic.
As a secondary aim, we studied the absolute accuracy and
trend accuracy of SpHb. The accuracy of SpHb has been
evaluated in hemodilution [23], surgery [24–29], and
intensive care [11, 30]. Most studies have evaluated absolute
accuracy while only a few studies have systematically
evaluated trend accuracy, which appears to be more relevant
in blood loss assessment. In our study, we verified that
Fig. 3 Bland and Altman plot
of 83 SpHb and Hb data pairs
collected from 45 neurosurgery
patients, showing bias (solid
line) and limits of agreement
(dashed line)
Fig. 4 Regression plot of directional changes in consecutive SpHb
values (delta SpHb, Y axis) compared to consecutive changes in Hb
values (delta Hb, X axis), collected from 45 neurosurgery patients.
Data points within the shaded area are below the clinically relevant
threshold of changes of B1 g/dL
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revision E sensors for SpHb monitoring had clinically
acceptable absolute accuracy. Laboratory hemoglobin val-
ues vary depending on a variety of factors including sam-
pling site. Typically laboratory hemoglobin is measured at
the peripheral vein (macrocirculation) reflecting hemoglo-
bin, while SpHb measures capillary (microcirculation)
hemoglobin. Macrocirculation and microcirculation have
different physiological responses to acute events, such as
blood loss, which must be taken into consideration when
making comparison to laboratory values [31, 32].
When SpHb values were compared to a reference lab-
oratory device in our study, we found a higher standard
deviation than what has been reported for Hb measure-
ments from consecutive blood samples run on the same
model lab device [33]. However, the standard deviation of
SpHb to Hb in our study was similar to that found for Hb
measurements from consecutive blood samples analyzed
on two separate laboratory devices [34]. Regarding trend
accuracy, the high correlation we observed indicates that
increases and decreases in laboratory Hb were captured
with the changes in SpHb. SpHb has the added benefit of
not just calculating the differences or lack of differences
between intermittent measurements, but also providing
data continuously.
In addition to the primary and secondary aims of this
study, our results demonstrate that the implementation of
SpHb monitoring could also provide significant cost sav-
ings. A 2007 study from Shander et a1. [8] showed annual
expenditures on blood and transfusion-related activities, for
surgical patients only, ranged from 1.6 to 6 million dollars,
or $522 to $1,183 per RBC unit. These estimates use
activity based costs, which are the true cost of giving blood
because they include not just the material cost of blood but
also the direct costs to administer blood throughout the
multistep procedure. Our results indicate a reduction of 0.9
units of blood per surgery or between $470 to $1,065 per
patient monitored and $470,000 to $1,065,000 per 1,000
surgeries of the same type (Table 2). Note that this does
not include the intra-hospital or even intra-country vari-
ability in cost of transfusion, nor the cost of devices and
sensors.
Our study has some limitations worth noting. We used a
convenience sample and did not randomize all patients
after enrollment due to logistics of assigning them to the
operating room with a sole SpHb monitor, but instead
randomized which patient would be enrolled in the SpHb
Group. This also led to an expected but unbalanced number
of patients in both groups, as we were able to enroll mul-
tiple patients on the same day in the Control Group.
Nonetheless, there was no bias in SpHb patient selection
and there was no difference in baseline characteristics
between groups. Therefore the differences in the SpHb
Group can be attributed to the availability and use of SpHb
monitoring. Furthermore, we were not able to blind the
study given that clinicians had to make decisions in real-
time data; this decreased the overhead delay in assessing
hemoglobin concentrations, and consequently clinicians
were able to start and stop transfusions in a timelier man-
ner. While this may be viewed as a study bias, we view the
difference of having a continuous data stream as the benefit
of SpHb monitoring rather than a limitation of the study.
Finally, we were not able to collect post-surgery trans-
fusion data or post-discharge information, which would
facilitate longer-term assessment of our investigation.
Also, our hospital’s blood transfusion practice may be
different from other hospitals and that may limit transfer-
ability of our findings to other institutions. Unless clinical
signs dictate otherwise, such as a massive bleeding event
during surgery, it is standard practice in our hospital to
initiate a hemoglobin measurement when EBL reaches
approximately 15 % of estimated blood volume (EBV) and
to initiate blood transfusion when the hemoglobin value is
confirmed to be Bl0 g/dL.
5 Conclusion
Measurement of Hb is one of the most frequent and
important assessments in patients undergoing major surgery
and in patients admitted to the critical care unit. Unfortu-
nately, invasive blood sampling and laboratory analysis
only offer the perspective of a single point in time, while
hemoglobin is in fact dynamic. This means that when the
results of the ‘‘still picture’’ taken 5–50 min earlier become
available, the ‘‘picture’’ may have changed. Our belief is
that the real-time ability of SpHb [35] offers a ‘‘motion
picture’’ that does not replace the metaphorical still picture,
but supplements its inherently intermittent and delayed
results. As shown in our study, the ability to observe the
continuous trend in hemoglobin affects transfusion behav-
ior, allowing earlier cessation of RBC transfusion as well as
earlier consideration of initiation of RBC transfusion.
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